Halozyme Therapeutics Incorporated (HALO) Share Price

About 450 March call options, strike price of $60 and $65 traded today -- not a huge amount. Perhaps the US patent extension is around the corner, though I think more than that will be needed to take the stock to new highs.

I’m sure that index funds are
A big part of it.

The question is—why is this company so appealing to the institutional investors?

The pps has been remarkably stable, which is something in this environment. Having an OS with 99% institutional holders helps but, you might be on to something. There may be rumors or nods and winks being passed along to those with direct access. It is certainly way overdue if that's the case. Have you looked at options action?

“Golden cross”— perhaps some unexpected good news is imminent.

Halozyme is 99.6% institutionally owned.

https://www.nasdaq.com/market-activity/stocks/halo/institutional-holdings

Added additional shares @ $56.12 today as planned.

Updated PE ratios:
2024 Actual14.552025 Estimates12.242026 Estimates9.32027 Estimates7.01
PEG ratio is 0.44
https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

Jessica Frye is clearly very skeptical of Helen's incessant happy promises and wants to see concrete results. I like her hard nosed approach and totally agree with what you quoted. She also pinned Nicole on the definition of "mid-single digits" and, of course, the answer was "3-7%", a shameful and embarrassing thing to have to admit. One can assume this new math was Helen's idea, and Nicole was forced to adopt the party line.

JPM remains neutral:
"With a strong near-/medium-term growth outlook outlined through 2028, we and the buyside are keenly focused on new/expanded partnerships to support growth in 2029+. To this end, on the call, mgmt noted a new development agreement for their small volume auto-injector with an undisclosed current partner for a commercial product. Bigger picture, while we are encouraged by the growth of HALO’s portfolio of subQ products, we would like to see more deals with new or existing partners with good economics and more visibility on Wave 4/5 products to get more constructive."

Sold some TMDX end of day to put proceeds into HALO if they take it back down to below $57 again next couple trading days!

Enjoy the bargain shopping!

All dips are blessings. We will be in new all time highs baring crazy market conditions.

Added more today on the brief drop below $57. Great call, and many good things to come! Price may meander still a bit, but overall direction is up long term. Probably won't see $70s until HVAI deal is formally announced. Hopefully see something by mid 2025 on that. Until then adding more on any more dips below $57

GLTA, and considering there are a lot of crap IHUB boards out there - this one keeps it pretty real. Thanks to all who post reasonable due diligence!

Long time ATRS holder who started investing in HALO after the acquisition. ✌️🤙

The corporate slide deck was vastly improved and is a good resource. Now a sticky at the top of the comments.

2024 year-end corporate slide deck from the Feb 25 call:
https://s28.q4cdn.com/284259014/files/doc_financials/2024/q4/HALO-4Q24-Earnings-Deck-FINAL-FINAL.pdf

Big HUG, HELEN!

HC Wainwright raises price target from &70 to $72 https://www.benzinga.com/quote/halo/analyst-ratings

Still a bit foggy on HVAI but positive spin. Undisclosed small volume injector deal in the bag. Current business off the charts. This may lift some of the doubt moving forward. Still not there all the way yet but very positive. A cash generating machine.

Have current partner that has agreed to deal/collaboration with small volume. Few details due to 'gag order' requested by partner

Have not had a chance to listen to CC. What did she say about new 1) Enhanze, 2) HVAI and 3) small volume autoinjector deals?

Earnings are out.
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter profit of $137 million.

The San Diego-based company said it had net income of $1.06 per share. Earnings, adjusted for one-time gains and costs, came to $1.26 per share.

The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.16 per share.

The biopharmaceutical company posted revenue of $298 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $284 million.

For the year, the company reported profit of $444.1 million, or $3.43 per share. Revenue was reported as $1.02 billion.

Halozyme Therapeutics expects full-year earnings in the range of $4.95 to $5.35 per share, with revenue in the range of $1.15 billion to $1.23 billion.

HALO, 10Q due 2/18

Elektrofi knows a lot about what Halozyme does and who they deal with and on what terms.

Chief Business Officer

Greg DeFilippis is the Chief Business Officer, responsible for Elektrofi’s go-to-market strategy, including revenue optimization, partnerships, and corporate development.

Greg is an experienced clinical and commercial leader with more than 20 years’ experience of pharmaceutical, biotech, and medical device industry experience. Having held C-suite and senior leadership positions he has a proven track record of successfully forming strategic partnerships, developing, launching and growing products with a focus on driving profitable revenue growth, building, and leading high-performing organizations.

Greg served as Chief Business Officer of Halozyme, leading the company’s licensing strategy for its technology and autoinjector device platforms as well as its strategic partnering strategy. Prior to Halozyme he served as Senior Vice President, Device Business and Alliances for Antares Pharma. Over the course of his career, Greg has helped partner, develop, and launch 17+ therapies including Xyosted®, Otrexup®, and the first generic AB rated EpiPen. He has held increasing roles of responsibilities for companies including Teva Pharmaceuticals, Barr Laboratories, Pliva, Actavis, and Alpharma.

Greg holds a Master of Business Administration in Finance from Fairleigh Dickinson University and a Bachelor of Science in Industrial and Systems Engineering from Virginia Tech. Greg is a certified Lean Six Sigma Master Black Belt.

Correction: pharmacokinetics not pharmacodynamics 

You are forgetting the extrcellular matrix. It makes absorption super slow via SC. So again if you want to have the same pharmacodynamics as IV, you need rhuph20. This is why you see the use of hyaluronidase all over Elektrofi's patent. You don't have to take my words for it. Look at their patents.

“Essentially, we take a drug substance (typically in liquid form) and convert it through a series of proprietary methodologies into an ensemble of very smooth and spherical microparticles,” Coffman explains. “Then we disperse those particles into an oily carrier medium that is eminently flowable and syringable, even at extremely high concentrations that are not otherwise accessible through conventional approaches to drug product formulation.”

Throughout the process, the protein molecule’s quality, shape, and size are preserved, and the concentration of injectable microparticle suspensions can exceed 600 mg/mL. In many cases, the concentration can be as much as five times that of standard formulations. Not only are Hypercon formulations capable of eliminating the need for infusions, they are also capable of reducing the frequency of injections by as much as half thanks to the concentrated dosages.
https://www.genengnews.com/topics/translational-medicine/protein-microparticles-turn-infusions-into-injectables/

This seems to contradict your theory, but I admit it is not totally clear.
In any event, Jannsen only paid $18 million upfront to have a go at it, with high backloaded payouts, which speaks to the speculative nature of the product as I read it.

If don't mind the concentrated biologic to sit in the subcutaneous space for a long time, then you won't need rhuph20. But if you are converting IV to SC and want similar pharmacodynamics, you definitely need rhuph20. 

I think the Hypercon technology allows the injection without the need for Enhanz, thereby being a direct competitor to HALO.

Good stuff. Yes, Elektrofi technology need's hyaluronidase. They (Elektrofi) merely concentrate theraputics/biologics. For the concentrated compund to be absorbed properly via SC route, you still need hyaluronidase. Let's hope they are using halo'a Enhanze and not the Korean's hyaluronidase. I suspect they are using halo's since they have been experimenting with hyaluronidase way before there a wanna be korean competitor.

I hope Helen doesn't buy Elektrofi before she has secured a HVAI partner first. We all saw how the market reacted with Evotec. She needs to show that there is innovation and continued EPS growth well into 2030's before pulling through trigger on an acquisition.

While hiding behind the couch, waiting for a reply, the breadcrumb investor fell asleep. Upon waking he saw messages up on the screen, one from the thread KiA and one from another poster. Nervously he read the posts, and was exuberant that they both left informative comments, and didn’t degrade or humiliate him. Still he was a little disappointed the KiA was to uppity to reply directly to original post. Even-though, the breadcrumb investor enthusiastically jumped out from behind the couch, did a little happy-dance, before jumping out the HALO-portal.

Unfortunately in his enthusiasm other valuable breadcrumbs, which he had wrapped in gold-foil, fell out go his pockets and burst open. Thus the HALO world learned what the inquisitive investor was really hiding, something he learned from following a breadcrumb left by a past poster. The breadcrumbs showed it is highly probable a deal will soon to be announced with Elektrofi, using its Hypercon technology to encapsulate Genentech’s rituximab, and HALO’s Enhance and AI technology for SC injection.

https://www.freepatentsonline.com/y2025/0026811.html

https://www.genengnews.com/topics/translational-medicine/protein-microparticles-turn-infusions-into-injectables/

https://www.elektrofi.com/news/elektrofi-janssen-biotech-enter-worldwide-collaboration

Amgen deal would be sweet! Thanks for sharing. And yes, I think Helen used to work for them.

However, isn't CARFILZOMIB already available as generic? May be Amgen wants to combine it with other biologics plus Enhanze. 

Interesting. Helen brought this drug to market in a previous lifetime.

Hiding his identity, the disgraced investor again sneaked thru the HALO-portal, crawled behind the couch, and tossed a breadcrumb onto the webpage for input from the thread know-it-all; cause the investor lacked the knowledge to determine whether the breadcrumb could lead to a deal with Amgen..........

29. The method of claim 28, wherein the hyaluronidase is PH20.

34. The method of any one of claims 1-33, wherein the carfilzomib is pegylated.

https://www.freepatentsonline.com/WO2025035020A2.html

I have been and remain a long but I must say, if Helen doesn't have a meaningful update on new partnerships (speciallly HVAI) next Tuesday, we might see a short term pull back.

... From MORGAN STANLEY:

"Halozyme has developed the first clinically demonstrated high volume auto-injector capable of delivering up to 10 mL rapidly in 30 seconds. This innovation combines Halozyme's expertise, auto-injector technology, and ENHANZE drug delivery technology to enable large volume subcutaneous injections that were previously not possible. The HVAI addresses a high unmet need, as there are no other devices that can rapidly deliver such high volumes subcutaneously."

Morgan Stanley assumes coverage of Halozyme at an Overweight rating and a price target of $67. 

Re Auto injectors, I post this link of JPM's analysis of VKTX first posted by WorstLuck on the Biotech Values Board. Seems Helen needs to get on the phone and get to work on this opportunity.
https://x.com/TomSilver39/status/1887297561264070838

... can't fight the fundamentals. Permabears have been swimming against a strong fundamentals current since we were in $teens, $20's, $30's, $40's and $50. Each time there has been a pull back, they claimed victory only to be proven wrong again and again. Can't go against growing earnings with profit margins offered at a PEG of 0.5 and forward PE of 11.

We need Helen to deliver an HVAI deal. It's been 2 years since she first promised it. We will easily be in $75-$95 range depending on the size of the deal. 

But even without one, we are headed to $60's. This is what permabears did not undestand when we they were forcasting doom and gloom in November. Anyone listening to them would have missed out on a 33% run we've had from low 40's.

....& THANK YOU HELEN !

THANK YOU!

Halozyme is tied for the No. 1 spot out of 730 stocks in the Medical-Biomed/Biotech group, which ranks No. 70 out of the 197 industry groups tracked by Investor's Business Daily. https://www.investors.com/stock-lists/sector-leaders/halozyme-stock-halo-biotech/

Sure am enjoying this "languishing" !

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. https://markets.businessinsider.com/news/stocks/halozyme-price-target-raised-to-70-from-68-at-h-c-wainwright-1034214389

Benchmark Co. analyst Robert Wasserman maintains Halozyme with a buy rating, and adjusts the target price from $60 to $75. https://news.futunn.com/en/post/52757517/benchmark-co-maintains-halozyme-therapeutics-halous-with-buy-rating-raises?level=1&data_ticket=1738679929267789

Royalties should not be affected. 

How will the new tariffs effect HALO?

Better to languish at this level than 42. Still needs some deals to prove out there thesis so don’t expect much until then.

... I must say, it is "languishing" quite well. Just like it "drifted" superbly after beating and raising immediately following quarterly results. LOL.

"Momentum traders"?! Not.